Top 10 Biopharma Dealmakers by Upfront Cash

by | Sep 4, 2018

Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to filter for deals involving major R&D and commercial rights, namely licensing of biotech, pharmaceutical, medical device, diagnostic, and technology platforms. This gave us an initial set of over 950 deals form January 2017 to August 2018 among the broader set of 12,000+ deals. We then sorted by upfront cash payments, overall deal values, deal counts, and applied our experience in context to produce tables of top companies and their deal totals.

Interesting Takeaways
  • The top 10 companies paid over $6.5 billion of the $11 billion-plus in total upfront cash in the 20 months since the beginning of 2017 – 60% of the total from 10 companies.
  • This was among 131 deals in the group and $51.3 billion in overall deal value
  • We could have added 12 more companies to the list and still see deals with $100 million or more paid up front
DealForma Datasets
  • Companies – Large biopharma companies in-licensing or paying for the option to license
  • Deals – Development and commercialization deals for technology platforms, preclinical and later compounds (Phase I, Phase II, Phase III, and Approved), medical devices, and diagnostics (full list of criteria in the DealForma platform).

Story Published in Endpoints News: Read the story

Run your own analysis with your DealForma access.

Schedule a Demo to See it in Action

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

25,544

Deal Profiles

15,147

Funding Rounds

28,034

Company Profiles

17,936

Product Profiles

119K+

Clinical Trials

3,982

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

More Research by DealForma

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

The top deal upfront for November 2021 was the Owkin – Sanofi artificial intelligence and federated learning platform research partnership to advance Sanofi’s oncology pipeline. Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.

October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

The top deal upfront for October 2021 was the Xencor – Janssen deal for plamotamab and XmAb bispecific antibodies and new XmAb B-cell targeting bispecific antibodies for CD20-expressing hematologic malignancies. Xencor will receive $100M in upfront cash, $25M in an upfront equity investment, and is eligible for up to $1.18B in dev., reg., and sales milestones, plus tiered mid-teens to low-twenties royalties.

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies. This expansion is for Phase I/II CTX001 for severe sickle cell diseases and transfusion-dependent beta-thalassemia. CRISPR will receive $900M up front, up to $200M in milestones upon the first regulatory approval, and a cost/profit split of 40%.

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant in Phase III for advanced squamous cell carcinoma of the head and neck. Debiopharm will receive EUR188M ($227M) up front and is eligible for up to EUR710M ($856M) in milestones, plus royalties. This was the largest upfront cash and equity for a partnership signed in March 2021.

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.

DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.

 

Company

About Us

Analysis / Blog

Contact Us

Product

Support

Pricing

Connect

Made in San Mateo, CA and around the world    support@dealforma.com   (650) 353-9363  Terms  Privacy

Copyright © 2020 DealForma